

RESEARCH ARTICLE

Open Access

The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections

Manuela Zlamy¹, Sabine Kofler¹, Dorothea Orth³, Reinhard Würzner³, Peter Heinz-Erian², Andrea Streng⁴ and Martina Prelog^{1,4*}

Abstract

Background: The aim of the study was to evaluate the effects of universal mass vaccination (UMV) against rotavirus (RV) on the hospitalization rates, nosocomial RV infections and RV-gastroenteritis (GE)-associated secondary blood stream infections (BSI).

Methods: The retrospective evaluation (2002–2009) by chart analysis included all clinically diagnosed and microbiologically confirmed RV-GE cases in a large tertiary care hospital in Austria. The pre-vaccination period (2002–2005) was compared with the recommended and early funded (2006–2007) and the funded (2008–2009) vaccination periods. Primary outcomes were RV-GE-associated hospitalizations, secondary outcomes nosocomial RV disease, secondary BSI and direct hospitalization costs for children and their accompanying persons.

Results: In 1,532 children with RV-GE, a significant reduction by 73.9% of hospitalized RV-GE cases per year could be observed between the pre-vaccination and the funded vaccination period, which was most pronounced in the age groups 0–11 months (by 87.8%), 6–10 years (by 84.2%) and 11–18 years (88.9%). In the funded vaccination period, a reduction by 71.9% of nosocomial RV-GE cases per year was found compared to the pre-vaccination period. Fatalities due to nosocomial RV-GE were only observed in the pre-vaccination period (3 cases). Direct costs of hospitalized, community-acquired RV-GE cases per year were reduced by 72.7% in the funded vaccination period. The reduction of direct costs for patients (by 86.9%) and accompanying persons (86.2%) was most pronounced in the age group 0–11 months.

Conclusions: UMV may have contributed to the significant decrease of RV-GE-associated hospitalizations, to a reduction in nosocomial RV infections and RV-associated morbidity due to secondary BSI and reduced direct hospitalization costs. The reduction in nosocomial cases is an important aspect considering severe disease courses in hospitalized patients with co-morbidities and death due to nosocomial RV-GE.

Keywords: Rotavirus, Gastroenteritis, Blood stream infection, Children, Universal mass vaccination

* Correspondence: Prelog_M@kinderklinik.uni-wuerzburg.de

¹Department of Pediatrics, Pediatrics I, Innsbruck Medical University, Anichstr. 35, 6020, Innsbruck, Austria

⁴Department of Pediatrics, University of Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany

Full list of author information is available at the end of the article

Background

Rotavirus (RV) infections are one of the most frequent causes of gastroenteritis in children worldwide with a major impact on mortality in children <2 years living in developing countries [1-4]. In European countries, mortality attributed to RV infections was estimated to be 1 in 100,000 children <5 years for each year [5-7], with a high burden of nosocomial RV gastroenteritis in the pediatric population [8].

In Austria, about 45,000 episodes of acute RV-associated gastroenteritis (RV-GE) account for approximately 1,400 hospital admissions per 100,000 children [2,5]. Austria, prompted by cost calculations [9], was one of the first European countries to recommend vaccination against RV since 2006 and to subsidize an universal mass vaccination (UMV) program in infants aged between 6 weeks and 6 months with Rotateq (Sanofi Pasteur MSD SNC, Lyon, France; market launch September 2006) between July and December 2007 and with Rotarix (GlaxoSmithKline Biologicals, Rixensart, Belgium; market launch May 2006) between January 2008 and December 2009. Both vaccines are directed against the most important serotypes circulating in Austria, G1P (74.0%), G4P (8.0%) and G3P (1.8%) which were found in samples from hospitalized children due to RV-GE in Innsbruck, Tyrol, and Leoben, Styria [10]. A vaccination coverage of 72 to 87% was documented by surveillance data in 2008 [11]. The hospitalized cases in RV-affected children aged between 3 and 20 months decreased from August 2007 until December 2008 by 74% [11]. A further reduction of RV-GE and some effects of herd protection in older children who were not covered by the UMV because of age limitations were described for 2009 [12]. Both commercially available RV vaccines have a similar efficacy and safety profile [1,13] and have been found to be cost-effective depending on different perspectives and modeling assumptions in some European and developing countries [13-17] with a reduction of all-cause diarrhea-related hospitalizations among children <5 years [18-22].

From the patho-physiological view, RV causes an intestinal epithelium dysfunction in the small intestine. RV-damaged enterocytes are more capable for bacterial invasion causing secondary bacterial infections [23,24]. Only few studies exist thus far which focus on secondary blood stream infections (BSI) as one major and life-threatening complication following RV-GE [24-29].

The retrospective evaluation by chart analysis (2002–2009) focused on all both clinically diagnosed and microbiologically confirmed RV-GE-associated cases in a large tertiary care children's hospital in Austria. The focus was on RV-GE-associated hospitalizations as the primary outcomes; secondary outcomes were the burdens of nosocomial RV disease and occurrence of secondary BSI as well as direct hospitalization costs for

children and their accompanying persons based on the accounts provided by the clearing office of the hospital.

Methods

Study design and study population

The retrospective evaluation focused on all cases of RV-GE hospitalized between 1st January 2002 and 31st December 2009 at the Department of Pediatrics, Medical University Innsbruck, a tertiary hospital with additional primary and secondary care functions, covering the area of Tyrol with an average population of 1,277,775 inhabitants between 2002 and 2009. For our analysis, all RV positive stool samples from the Division of Hygiene and Medical Microbiology and the Routine Laboratory of the Department of Pediatrics were matched with the data from the hospital discharge records using the International Classification of Diseases, 10th edition (ICD-10) with search terms “gastroenteritis” (K52.9), “rotavirus” (A08.0), “exsiccosis” (A09) and “blood stream infection” (A41.9) as primary and secondary diagnosis to identify potential RV cases. For inclusion into the study, clinical diagnosis of RV infection had to be confirmed by laboratory results. For included patients a chart review was performed.

Subgroups of the study population

Groups were separated into a “pre-vaccination period” (January 2002 to December 2005), a “recommended and early funded vaccination period” (intermediate period) (January 2006 to December 2007) and a “funded vaccination period” (January 2008 to December 2009). For determination of the influence of UMV on the age distribution and the hospitalization rates in children with RV infections, children were separated into 5 different age groups according to epidemiological data: infants aged 0–11 months, toddlers aged 12–23 months, children aged 2–5 years, school children aged 6–10 years and children 11–18 years of age. The reasons for age classification are: Most children acquire their first RV-GE before the age of 5 years [1-7]. Severe RV-GE is largely limited to children aged <24 months [1,2]. Vaccinated children aged between 0 and 11 months should have received at least one dose of the vaccine. Toddlers aged between 7 and 24 months are most likely to have been fully vaccinated during UMV [9]. The RV vaccination status could not be collected by chart review. Double-counters and patients admitted more than once due to RV-GE were excluded.

The study was performed according to the principles of the declaration of Helsinki 2008 and the local ethics committee of the Innsbruck Medical University.

Data collection and definitions

Clinical data from patients included into the study were collected by chart analysis. Cases were defined as

nosocomial (hospital-acquired) RV infections if the onset of gastroenteritis-specific symptoms (diarrhea, vomiting) was at least 48 hours after admission to hospital [9] considering an incubation time for RV of 18–36 hours [30] and an admission diagnosis that was not “gastroenteritis”. Gastroenteritis was defined by more than 3 loose stools or watery diarrhea within 24 hours [3] with or without vomiting (particularly in older children), fever and dehydration according to signs given in a scoring system for RV GE [31]. The duration of the hospital stay was defined as the time span between the day of admission and the day of discharge. Nosocomial RV-GE cases were excluded from the analysis of hospital stay durations.

A blood stream infection (BSI) was defined as at least one of the following features: first, a blood culture positive for a pathogen; second, a common pathogen of human skin cultured from two or more blood cultures, both drawn on separate occasions; or third, a common pathogen of the human skin cultured from at least one blood culture in association with signs of a systemic inflammatory response syndrome (SIRS). A SIRS was defined by at least two of the following criteria: elevated body temperature $>38^{\circ}\text{C}$ or hypothermia $<36^{\circ}\text{C}$, tachycardia, tachypnea, leucocytosis, leukopenia or $>10\%$ immature neutrophils according to age ranges. A secondary BSI was defined as a BSI following the clinical symptoms of gastroenteritis associated with laboratory confirmed RV infection more than 48 after onset of RV-associated disease. The present study focused exclusively on secondary BSI.

Hygienic regulations for prevention of nosocomial infections on the ward were not changed during 2002 to 2009. All nurses and doctors with direct contact to the RV-infected patient had to wear over-coats and had to follow a three minutes long hand washing program with Bode Sterillium[®] Virugard (Paul Hartmann AG, Telgte, Germany) disinfectant solution after patient contact. RV-positive patients and their accompanying persons were cohorted on the ward in separate rooms with own bath rooms and were prohibited to use any facilities on the ward which may have offered the possibility to get in contact with other patients.

Laboratory confirmation of RV and other pathogens from stool samples

Between 2002 and 2009, all hospitalized patients with gastroenteritis were screened for RV antigen in their stools. For detection of human RV antigen in stool specimen the Pathfinder Direct Antigen Detection System (Kallestad Laboratories, Inc. Austin, Texas) was used till 2005. The sensitivity and specificity of this test system is 84% and 98%, respectively. After 2005, the CerTestRota Card (Biotec, Zaragoza, Spain), an immunochromatographic test for Rotavirus detection in stool specimen was used for routine

testing. The sensitivity and specificity of this test system is $>99\%$ and 98%, respectively. Routinely, stools were also investigated for additional viral pathogens (Norovirus, Adenovirus) via antigen detection and for bacterial pathogens (*Salmonella*, *Yersinia*, *Shigella*, *Campylobacter* spp. and enterohemorrhagic *Escherichia coli*) via stool cultures according to standard procedures.

Identification of pathogens in blood culture

From patients showing at least two signs of SIRS, an average of 4 ml blood was drawn for detection of blood-stream pathogens and inoculated into a BacT/Alert PF Pediatric FAN bottle (BioMérieux, Durham, USA). This procedure did not change over the observation period. The bottles were then loaded into a BacT/Alert 3D automated blood culture system (BioMérieux) for a five day protocol with monitoring of carbon dioxide production within each bottle every 10 min. All bottles marked positive were removed from the instrument, and an aliquot was taken for Gram staining and culture on solid media for subsequent analysis. Pathogen identification was performed according to standardized microbial procedures and by VITEK 2 system (BioMérieux).

Cost calculations

The direct hospitalization costs for children and their accompanying persons are based on the accounts provided by the clearing office of the “Tiroler Landeskrankenanstalten” (TILAK) holding. For the pre-vaccination period the mean of the costs were 870 € per patient per day and for the accompanying person 35 € per day given a proportion of 87.2% accompanying persons in children <6 years (funded vaccination period: 930 €, 38 € and 90.8%, respectively). Children ≥ 6 years of age are usually not accompanied due to the insurance system which does not refund parents’ costs for the hospital stay together with their child. Nosocomial infections were excluded from cost calculations because of co-morbidity-associated costs which do not allow an approximation of hospitalization costs. Estimated mean of costs per year for community-acquired RV-GE cases were calculated by multiplication of the mean hospital duration (days) (Table 1), mean number of patients per year per age-group (Table 2), mean of direct costs (€) and proportion of accompanying persons in age groups <6 years. Costing procedures have not changed during the study period.

Calculation of hospitalization rates

The Innsbruck hospital covers approximately 70% of all pediatric RV-GE hospitalizations in Tyrol. estimated hospitalization rates were calculated for the pre-vaccination, the intermediate and funded vaccination period using the draw area of Tyrol for patients 0–18 years for the different periods (pre-vaccination

Table 1 Clinical and laboratory characteristics of patients with secondary BSI

Type of RV-GE (number)	Mean age (months; range)	Sex (female/male)	Onset of BSI after RV-GE (hours; range)	Underlying disease (number)	Pathogens in blood culture (number)	Other pathogens in stool samples (number)	Mean CRP (mg/dl; range)	
Community-acquired (6)	13.9 (11–60)	2/4	149 (48–384)	WPW-syndrome (1)	Staphylococcus aureus (2)	Negative (6)	3.6 (0.2–17.1)	
				Bronchitis (1)	Neisseria species (1)			
				None (4)	Enterobacter species (3)			
					Klebsiella species (1)			
Nosocomial (14)	15.6 (0.2–60)	6/8	189 (48–648)	Preterm birth (7)	Staphylococcus aureus (10)	Negative (12)	9.4 (0.3–19.3)	
				SOT (2)	Streptococcus pneumoniae (1)			Clostridium difficile (2)
				ALL (3)	Enterobacter species (2)			Adenovirus (1)
				Gastroschisis (1)	Enterococcus faecalis (1)			
				Propionacetemia (1)				

Abbreviations: Rotavirus-gastroenteritis (RV-GE); Wolff-Parkinson-White-syndrome (WPW); solid organ transplantation (SOT); acute lymphatic leukemia (ALL); C-reactive protein (CRP).

Preterm birth was defined by gestational age <37 weeks. In some patients more than one pathogen was found. There was no significant difference between the community-acquired and nosocomial RV-GE groups.

period: 652,557; intermediate period: 319,825; funded vaccination period: 305,393 [31] as denominator for calculation of incidence rates.

Statistical analysis

Statistical analysis was performed with SPSS Version 18.0 (Chicago, IL). Non-parametric Mann-Whitney-U test was used to compare mean hospitalizations per year between the pre-vaccination and the vaccination period. Pearson's Chi-square test was used to analyze difference in dichotome variables. A $p < 0.05$ was defined statistically significant.

Results

Effectiveness of RV vaccination

During the study period, a total number of 3,090 RV-positive stool samples were collected. After excluding

double-counters, 2,533 remaining RV-positive cases were matched with the documented ICD-10 discharge codes. A total of 1,001 RV-positive cases were excluded as there was no clinical diagnosis of RV-GE in these patients.


The mean age of the RV-GE afflicted 1,532 patients (809 male, 723 female) was 2.3 years (median 1.4 years; range 3 days–16.5 years) (Table 2). A significant reduction of hospitalized RV-GE cases per year could be observed between the pre-vaccination and the funded vaccination period ($p < 0.001$) (Table 2, Figure 1). The absolute number of mean cases per year decreased most strongly in children below 6 years of age (Figure 1). The proportional reduction of hospitalized RV-GE cases per year and age group was most pronounced in the age groups 0–11 months, 6–10 years and 11–18 years (Table 2).

Table 2 Reduction of RV-GE in age groups from the pre-vaccination period to the funded vaccination period

	Pre-vaccination period (2002–2005)		Intermediate period (2006–2007)		Funded vaccination period (2008–2009)		Reduction ^a
	Numbers of patients (%)	Mean numbers/year (95% CI)	Numbers of patients (%)	Mean numbers/year (95% CI)	Numbers of patients (%)	Mean numbers/year (95% CI)	
0–11 mos	360 (35.1)	90.0 (80.2–99.8)	113 (30.4)	56.5 (44.7–68.3)	22 (16.4)	11.0 (2.7–19.3)	87.8
12–23 mos	300 (29.2)	75.0 (62.8–87.2)	125 (33.6)	62.5 (37.6–87.4)	55 (41.1)	27.5 (7.4–47.6)	63.3
2–5 yrs	254 (24.8)	63.5 (50.8–76.2)	110 (29.6)	55.0 (36.5–73.5)	48 (35.8)	24.0 (11.5–36.5)	62.2
6–10 yrs	76 (7.4)	19.0 (15.1–22.9)	19 (5.1)	9.5 (8.3–10.7)	6 (4.5)	3.0 (1.6–4.4)	84.2
11–18 yrs	36 (3.5)	9.0 (4.1–13.9)	5 (1.3)	2.5 (1.8–3.4)	3 (2.2)	1.0 (0.8–2.2)	88.9
All	1026 (100)	256.5 (222.2–290.8)	372 (100)	186.0 (119.5–252.5)	134 (100)	67.0 (22.7–111.3)	73.9

Abbreviations: *mos* months, *yrs* years, *CI* confidence interval.

^aReduction is calculated between mean numbers per year of the pre-vaccination period and the funded vaccination period (decrease in percentage).



In the funded vaccination period, significantly fewer cases were nosocomial compared to the pre-vaccination period ($p < 0.001$) (Table 3). The absolute number of mean nosocomial cases per year decreased most strongly in the age group 0–11 months (Table 3). The proportional reduction was most pronounced in the age groups 0–11 months, 6–10 years and 11–18 years (Table 3, Figure 2). There was no change in seasonal peaks of RV-GE between the pre-vaccination and the other periods (Figure 3).

In 2003 to 2005, 3 patients died because of nosocomial RV-GE due to deterioration of their underlying diseases and co-morbidity (tetralogy of Fallot; transplantation of the small intestine and secondary BSI with multi-organ failure; Rett-syndrome). No patient died because of RV-GE in the other periods.

Searching for co-infections, in the pre-vaccination period, at least one additional pathogen was detected in the stool samples of 41 (4.0%) out of 1026 patients with confirmed RV-GE (mean 10.3 cases per year; 95% CI 8.4–12.1) and in the stool samples of 13 (9.7%) out of 134 patients (mean 6.5 cases per year; 95% CI 3.7–9.3) in the vaccination period ($p < 0.01$). Overall, the most frequent co-infecting pathogens were adenovirus (36 cases), *Salmonella ssp.* (26 cases), norovirus (18 cases) and *Campylobacter* (12 cases).

Secondary BSI after RV-GE occurred in 20 cases (pre-vaccination period: 14 cases, 1.4% out of 1026 patients; intermediate period: 3 cases, 0.8% out of 372 patients; funded vaccination period: 3 cases, 2.2% out of 134

patients) (Table 1), with 14 cases (70%) found in patients with nosocomial RV-GE. All patients were younger than 6 years with a mean C-reactive protein at the occurrence of BSI specific symptoms of 5.3 mg/dl. The most frequently detected pathogens were *Staphylococcus aureus* (60.0%), followed by *Enterobacteriaceae*. RV viremia was reported in one case.

Hospitalization rates, duration of hospital stay and cost calculations

Hospitalization rates were reduced from an annual mean of 55.3/10,000 person-years in the pre-vaccination period and 11.6/10,000 person-years in the intermediate period to 4.3/10,000 person-years in the funded vaccination period (reduction by 92.2%).

The mean duration of hospital stay for community-acquired RV-GE cases was shorter in the funded vaccination period compared to the pre-vaccination period ($p < 0.01$), which was most pronounced in the 6–10 years old children ($p < 0.01$) (Table 4). The mean duration of hospital stay for nosocomial RV-GE cases was 8.0 days (95% CI: 7.7–8.4) in the pre-vaccination period, 9.8 days (95% CI: 6.9–12.7) in the intermediate period and 13.3 days (95% CI: 5.8–20.7) in the funded vaccination period.

In the funded vaccination period, total direct costs were reduced by 72.7% compared to the pre-vaccination period ($p < 0.01$) (Table 4). The reduction of direct costs for patients and accompanying persons was most pronounced in the age group 0–5 months.

Table 3 Reduction of community-acquired and nosocomial RV-GE in age groups

Age	Pre-vaccination period (2002–2005)				Intermediate period (2006–2007)				Funded vaccination period (2008–2009)				Reduction ^a	
	Total numbers (% of total numbers)		Numbers per year (mean; 95% CI)		Total numbers (% of total numbers)		% of pre-vaccination		Total numbers (% of total numbers)		Numbers per year (mean; 95% CI)		Decreased by (%)	
	CA	NO	CA	NO	CA	NO	CA	NO	CA	NO	CA	NO	CA	NO
0–11 mos	303 (32.9)	57 (53.8)	75.8 (67.7–83.8)	14.3 (12.2–16.3)	94 (27.9)	19 (59.4)	47.0 (37.3–56.7)	9.5 (7.4–11.6)	21 (16.3)	1 (25.0)	10.5 (1.5–19.5)	0.5 (-0.2–1.2)	86.1	96.5
12–23 mos	279 (30.4)	21 (19.8)	69.8 (57.8–81.8)	5.3 (4.3–6.3)	113 (33.5)	9 (28.1)	58.0 (56.6–59.4)	4.5 (2.4–6.6)	53 (41.1)	2 (50.0)	26.5 (6.4–46.6)	1.0 (0–1)	62.0	81.1
2–5 yrs	234 (25.4)	20 (18.9)	58.5 (46.3–70.8)	5.0 (3.8–6.2)	106 (31.5)	4 (12.5)	53.0 (51.6–54.4)	2.0 (-0.8–4.8)	46 (35.7)	1 (25.0)	23.5 (11.7–35.3)	0.5 (-0.2–1.0)	59.8	90.0
6–10 yrs	71 (7.7)	5 (4.7)	17.8 (13.9–21.6)	1.3 (0.6–2.0)	19 (5.6)	0	9.5 (1.9–17.1)	0	6 (4.6)	0	3.0 (1.6–4.4)	0	83.1	100
11–18 yrs	33 (3.6)	3 (2.8)	8.3 (3.6–12.9)	0.8 (0.5–1.1)	5 (1.5)	0	2.5 (1.8–3.2)	0	3 (2.3)	0	1.5 (0.8–2.2)	0	81.9	100
All	920 (100)	106 (100)	229.5 (196.7–262.3)	26.5 (24.1–29.0)	337 (100)	32 (100)	170.0 (160.7–178.6)	16.0 (13.2–18.8)	129 (100)	4 (100)	64.5 (20.8–108.2)	2.0 (0–2.0)	71.9	92.5

Abbreviations: *mos* months, *yrs* years, *CA* community-acquired, *NO* nosocomial, *CI* confidence interval.

^aReduction is calculated between mean numbers per year of the pre-vaccination period and the funded vaccination period (decrease in percentage).




Figure 2 Numbers of community-acquired and nosocomial RV-GE cases.

Discussion

The present study clearly demonstrates that UMV not only led to reduction of RV-GE-associated hospitalizations by 73.9%, but also to a pronounced reduction of nosocomial RV infections by 92.5%. The possible indirect effect of UMV on nosocomial RV infections may be an important aspect considering severe disease courses in hospitalized patients with co-morbidities. This was corroborated by the fact that mortality in our pre-vaccination cohort was

attributed to deterioration of the underlying disease by nosocomial RV infection. A reduction of nosocomial RV infection was also seen in the US shortly after introduction of RV vaccination [32].

Also, in our study, secondary BSI was, in the majority of cases, linked to nosocomial RV-GE. In infants, RV infection has been described as a cause of pneumatosis intestinalis, hemorrhagic gastroenteritis, necrotizing enterocolitis and secondary BSI with mainly pathogens




Figure 3 Seasonal distribution and monthly numbers of hospitalized RV-GE cases. In the study, the pre-vaccination period lasts from January 2002 to December 2005, the recommended and early funded vaccination period (intermediate period) from January 2006 to December 2007 and the funded vaccination period from January 2008 to December 2009. Rotarix was launched May 2006 and Rotateq was launched September 2006 (dotted lines and arrows). Rotateq was subsidized by the universal mass vaccination (UVM) program July to December 2007, Rotarix was subsidized by the UVM January 2008 to December 2009 (continuous lines and arrows) in Austria.

Table 4 Duration and total costs for all community-acquired RV-GE induced hospital stays in the study hospital

Age	Pre-vaccination period (2002–2005)		Funded vaccination period (2008–2009)		Reduction	
	Duration of hospital stay (days) per year (mean; 95% CI)	Estimated mean of total costs per year (for patients/ accompanying persons)	Duration of hospital stay (days) per year (mean; 95% CI)	Estimated mean total costs per year (patient/ accompanying person)	Duration of hospital stay decreased by (%)	Costs per year decreased by (%)
0–11 mos	3.4 (3.1–3.7)	224,216 €/ 7,865 €	3.0 (2.3–3.6)	29,295 €/ 1,087 €	11.8	86.9/86.2
12–23 mos	4.0 (3.6–4.3)	242,904 €/ 8,521 €	3.5 (3.4–3.5)	86,256 €/ 3,201 €	12.5	64.5/62.4
2–5 yrs	3.7 (3.6–3.9)	188,312 €/ 6,608 €	3.5 (3.1–3.8)	76,493 €/ 2,838 €	5.4	59.4/57.1
6–10 yrs	4.1 (3.7–4.4)	63,493 €/0	2.5 (1.8–3.2)	6,975 €/0	39.0	-
11–18 yrs	3.9 (2.8–4.9)	28,162 €/0	3.8 (2.7–4.8)	5,301 €/0	2.6	-
All	3.8 (3.5–4.1)	747,087 €/22,994 €	3.3 (2.7–3.8)	204,320 €/ 7,126 €	13.2	72.7/69.0

Calculation:

Pre-vaccination group: Estimated mean of total costs per year = annual mean number of patients with community-acquired RV-GE in the respective age group x mean duration of hospital stay x mean cost per patient/accompanying person.

Post-vaccination group: mean of total costs per year = annual mean number of patients with community-acquired RV-GE in the respective age group x mean duration of hospital stay x mean cost per patient/accompanying person.

belonging to the intestinal microflora and the members of the *Enterobacteriaceae* family [24-29,33,34]. In our cohort, many of the 20 patients with secondary BSI were preterm infants or patients with compromised immune system and showed BSI due to *Staphylococcus aureus*. These findings allow us to hypothesize that not only intestinal mucosa dysfunction due to RV-GE promotes transition of intestinal bacteria, but that also a fatal combination of severe underlying diseases with dehydration and malnutrition in succession of RV-GE could have made patients more prone for secondary BSI caused also by non-intestinal bacteria. Although both RV vaccines cover the most important serotypes even in Austria [11], so far we are not able to know whether a shift to other RV serotypes will take place in the future causing inefficiency of the vaccine serotypes [35,36] and whether other gastroenteritis pathogens will take over.

The reduction of community-acquired hospitalized RV-GE cases found in our study confirms the data of recently published studies [5,11,12] which showed a significant reduction of RV cases reported by sentinel hospitals in the vaccination period in all age groups. In our study, the age group 0–11 months had the highest benefit of vaccination, highlighting the importance of starting the vaccination as early as possible [12]. A clear reduction in the older individuals indicates the presence of herd protection in the population by reduction of RV transmission [12,37,38]. However, also transmission of the attenuated RV types from vaccinated children to unvaccinated individuals may induce some immunity against RV in the unvaccinated older population [39-41].

In the US, a 50% decrease in RV-positive laboratory tests has been found after recommendation of RV vaccination for routine use in 2006, showing a delay in

seasonal onset of the RV season 2007–2008 by 2–4 months [2]. These data are in contrast to our data and previous data from Austria [11] which could not detect a shift of RV-associated hospitalizations to later months. However, the findings of the US study are limited by missing data from the end of the RV season 2007–2008 and by the fact that RV was tested based on the discretion of the physicians and local policies.

In our cohort, we could demonstrate a reduction of mean annual real costs by 72.7% between the pre-vaccination and the funded vaccination period, although it was not possible to include indirect costs, such as work loss by parents staying with the hospitalized child and supervision of siblings staying at their own. Considering the direct and indirect costs of hospital admissions due to RV-GE, UMV programs have been shown to be cost-effective [42] and would lead to a reduction of costs for RV-GE-related hospitalizations/emergency visits by 83% and for medical consultations by 75% [43]. In our study, in the funded vaccination period, hospital stays were about half a day shorter than in the pre-vaccination period which may also be accounted for by milder disease courses [44].

Limitations of our study exist in the fact that only hospitalized cases were counted and that local health-seeking behaviors of the population and hospital-specific guidelines for admission may influence the hospitalization rates [3]. We here reported the results of a single, large, tertiary care center and might have consistently missed mild cases of RV-GE which were treated at home. One disadvantage of a single-center experience also exists for differences in incidence oscillations by seasonal forcing and demographic forcing that may cause different patterns of hospitalizations in different places. Certainly not all RV cases would have been detected and might have been influenced by different detection systems and coding practices. The detection system was changed in 2005 to a

more sensitive method but with similar specificity. Additionally, the nature of the disease itself has to be taken into account, as wild-type RV infection does not prevent re-infection, or does not consequently enhance protection against recurrent infection [45–47]. However, the relative risk of re-infection is lower after one RV infection (0.62), two infections (0.4) or three subsequent infections (0.34) [47]. Subsequent infections are often subclinical or mild [47] and will not consequently lead to hospitalization of the children. Milder and asymptomatic cases will be less infectious, both as a result of reduced viral shedding rate and a shorter duration of infection. Thus, vaccination will cause fewer infections by making vaccinated individuals less able to become re-infected, if vaccination elicits the same immunological response as natural infections, and less able to transmit RV to others as predicted by transmission dynamic models [48]. In addition, also the numbers of older children may be underestimated, as most of them will suffer from mild infection without need for hospitalization [11]. Hospitalized re-infections were not assessed in our study, as double-counters were excluded to avoid biasing our results. Interestingly, in our study, 557 patients were double-counters, however, most of them were repeated detections of RV antigen in the stool samples during the same hospital stay or in immunocompromised patients showing a slow clearance from intestinal RV replication [41]. Unfortunately, due to the retrospective character of our study, the vaccination status was not sufficiently documented in the investigated patients, thus, despite being certainly of interest, break-through RV infections could not be assessed. Natural epidemiological oscillations are other factors which might have influenced our results. However, epidemiological studies since 1997 based on a sentinel system showed that fluctuations of RV-GE numbers were always less than the decrease observed since introduction of UMV [5]. An unrecognized change in the prevention of pathogen transmission was excluded in our study, as similar hygienic rules and introduction of nurses, parents and visiting persons were applied during the whole study period, interventions which have been shown to be crucial in reduction of transmission [20].

Conclusions

In conclusion, UMV against RV may have contributed to the significant decrease of hospitalizations of RV-GE since 2008 [11,12] and, most important, to a reduction of nosocomial RV infections and RV-associated morbidity due to secondary BSI and reduced direct hospitalization costs. The reduction in nosocomial cases is an important aspect considering severe disease courses in hospitalized patients with co-morbidities and death due to nosocomial RV-GE.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MZ performed the data analysis, participated in writing of the manuscript and designed the figures and tables. SK performed the data acquisition and analysis. DO performed the laboratory tests, the data acquisition and participated in interpretation of the data. RW and AS participated in interpretation of the data and revised the manuscript critically for important intellectual content. PHE performed the laboratory tests and participated in interpretation of the data. MP designed and coordinated the study, performed the data analysis and wrote the manuscript. All authors gave final approval of the manuscript.

Acknowledgements

The authors thank Mag. Hans-Jörg Schlögl (Abteilungsleiter Patientenservice, clearing office), ö. Landeskrankenhaus-Univ.-Kliniken Innsbruck, Tiroler Landeskrankenanstalten GmbH, Innsbruck, Austria, for making available the data on direct cost calculations.

This publication was funded by the German Research Foundation (DFG) and the University of Würzburg in the funding programme Open Access Publishing.

Author details

¹Department of Pediatrics, Pediatrics I, Innsbruck Medical University, Anichstr. 35, 6020, Innsbruck, Austria. ²Department of Pediatrics, Pediatrics II, Innsbruck Medical University, Anichstr. 35, 6020, Innsbruck, Austria. ³Department of Hygiene, Microbiology and Social Medicine, Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Fritz-Pregl-Str. 3, 6020, Innsbruck, Austria. ⁴Department of Pediatrics, University of Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany.

Received: 5 October 2012 Accepted: 27 February 2013

Published: 1 March 2013

References

1. Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, Jiang B, Gentsch JR: **Rotavirus vaccines: current prospects and future challenges.** *Lancet* 2006, **368**:323–332.
2. Anonymus: **Rotavirus Surveillance worldwide 2001–2008.** *Morb Mortal Wkly Rep* 2008, **57**:1255–1257.
3. Forster J, Guarino A, Perez N, Moraga F, Román E, Mory O, Tozzi AE, de Aquileta AL, Wahn U, Graham C, Berner R, Ninan T, Barberousse C, Meyer N, Soriano-Gabarró M, and the Rotavirus Study Group: **Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age.** *Pediatrics* 2009, **123**: e393–e400.
4. Giaquinto C, Van Damme P: **Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study.** *Scand J Infect Dis* 2010, **42**:142–147.
5. Rendi-Wagner P, Kundi M, Mikolasek A, Mutz I, Zwiauer K, Wiedermann U, Vécsei A, Kollaritsch H: **Active hospital-based surveillance of rotavirus diarrhoea in Austrian children, period 1997 to 2003.** *Wien Klin Wochenschr* 2006, **118**:280–285.
6. Williams CJ, Lobanov A, Pebody RG: **Estimated mortality and hospital admission due to rotavirus infection in the WHO European region.** *Epidemiol Infect* 2009, **137**:607–616.
7. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD: **2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis.** *Lancet Infect Dis* 2012, **12**:136–141.
8. Ogilvie I, Khoury H, Goetghebuer MM, El Khoury AC, Giaquinto C: **Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review.** *BMC Infectious Dis* 2012, **12**:62.
9. Fruhwirth M, Berger K, Ehlken B, Moll-Schüler I, Brösl S, Mutz I: **Economic impact of community- and nosocomially acquired rotavirus gastroenteritis in Austria.** *Pediatr Infect Dis J* 2001, **20**:184–188.
10. Fruhwirth M, Brösl S, Ellemunter H, Moll-Schüler I, Rohwedder A, Mutz I: **Distribution of rotavirus VP4 genotypes and VP7 serotypes among nonhospitalized and hospitalized patients with gastroenteritis and patients with nosocomially acquired gastroenteritis in Austria.** *J Clin Microbiol* 2000, **38**:1804–1806.

11. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H: **Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children.** *Pediatr Infect Dis J* 2010, **29**:319–323.
12. Paulke-Korinek M, Kundi M, Rendi-Wagner P, de Martin A, Eder G, Schmidle-Loss B, Vecsei A, Kollaritsch H: **Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria.** *Vaccine* 2011, **29**:2791–2796.
13. Dennehy PH: **Rotavirus vaccines: an overview.** *Clin Microbiol Rev* 2008, **21**:198–208.
14. Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, Edmunds WJ, Yazdan Y, Beutels P: **The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe.** *Vaccine* 2009, **27**:6121–6128.
15. Rheingans RD, Antil L, Dreifelbis R, Podewils LJ, Bresee JS, Parashar UD: **Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.** *J Infect Dis* 2009, **200**:S16–S27.
16. Tu HA, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ: **Economic evaluations of rotavirus immunization for developing countries: a review of the literature.** *Expert Rev Vaccines* 2011, **10**:1037–1051.
17. Bilcke H, Beutels P: **Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources.** *Pharmacoeconomics* 2009, **27**:281–297.
18. Yen C, Tate JE, Wenk JD, Harris JM, Parashar UD: **Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction.** *Pediatrics* 2011, **127**:e9–e15.
19. Clark HF, Lawley D, Matthijssens J, Dinubile MJ, Hodinka RL: **Sustained decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia in the new rotavirus vaccine era.** *Pediatr Infect Dis J* 2010, **29**:699–702.
20. Anderson EJ, Rupp A, Shulman ST, Wang D, Zheng X, Noskin GA: **Impact of rotavirus vaccination on hospital-acquired rotavirus gastroenteritis in children.** *Pediatrics* 2009, **127**:e264–e277.
21. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD: **Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states.** *J Infect Dis* 2010, **201**:1617–1624.
22. Curns AT, Coffin F, Glasser JW, Glass RI, Parashar UD: **Projected impact of the new rotavirus vaccination program on hospitalizations for gastroenteritis and rotavirus disease among US children <5 years of age during 2006–2015.** *J Infect Dis* 2009, **200**:S49–S56.
23. Lundgren O, Svensson L: **Pathogenesis of rotavirus diarrhea.** *Microbes Infect* 2001, **3**:1145–1156.
24. Carneiro NB, Diniz-Santos DR, Amorim C, Galeno C, Raposo J, Brandão L, Magalhães M, Cathalá R, Sardeiro S, Mello C, Silva LR: **Septic shock complicating acute Rotavirus-associated diarrhea.** *Pediatr Infect Dis J* 2006, **6**:571–572.
25. Lowenthal A, Livni G, Amir J, Samra Z, Ashkenazi S: **Secondary bacteremia after Rotavirus gastroenteritis in infancy.** *Pediatrics* 2006, **117**:224–226.
26. Cicchetti R, Iacobini M, Midulla F, Papoff P, Mancuso M, Moretti C: **Pantoea glomerans sepsis after rotavirus gastroenteritis.** *Pediatr Infect Dis J* 2006, **25**:280–281.
27. Kashiwagi Y, Sato S, Nakamura M, Kuboshima S, Numabe H, Kawashima H, Takekuma K, Hoshika A, Matsumoto T: **Klebsiella oxytoca septicemia complicating rotavirus-associated acute diarrhea.** *Pediatr Infect Dis J* 2007, **26**:191–192.
28. Chiappini E, Galli L, de Martino M: **Viremia and clinical manifestations in children with rotavirus infection.** *J Infect Dis* 2006, **193**:1333.
29. Mel E, Nahum E, Lowenthal A, Ashkenazi S: **Extended spectrum beta-lactamase-positive Escherichia coli bacteremia complicating rotavirus gastroenteritis.** *Pediatr Infect Dis J* 2006, **25**:962.
30. Ruuska T, Vesikari T: **Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes.** *Scand J Infect Dis* 1990, **22**:259–267.
31. Statistik Austria: [www.statistik.at], access: 5th February, 2013.
32. Anderson EJ, Rupp A, Shulman ST, Wang D, Zheng X, Noskin GA: **Impact of rotavirus vaccination on hospital-acquired rotavirus gastroenteritis in children.** *Pediatrics* 2011, **127**:e254–e270.
33. Rotbart HA, Nelson WL, Glode MP, Triffon TC, Kogut SJ, Yolken RH, Hernandez JA, Levin MJ: **Neonatal rotavirus-associated necrotizing enterocolitis: case control study and prospective surveillance during an outbreak.** *J Pediatr* 1988, **112**:87–93.
34. Capitanio MA, Greenberg SB: **Pneumoatosis intestinalis in two infants with rotavirus gastroenteritis.** *Pediatr Radiol* 1991, **21**:361–362.
35. Kirkwood CD: **Genetic and antigenic diversity of human rotaviruses: potential impact on vaccination programs.** *J Infect Dis* 2010, **202**:S43–S48.
36. Rougemont A, Kaplon J, Pillet S, Mory O, Gagneur A, Minoui-Tran A, Meritet JF, Mollat C, Lorrot M, Foulongne V, Gillet Y, Nguyen-Bourgain C, Alain S, Agius G, Lazrek M, Colimon R, Fontana C, Gendrel D, Pothier P, French Rotavirus Network: **Molecular and clinical characterization of rotavirus from diarrheal infants admitted to pediatric emergency units in France.** *Pediatr Infect Dis J* 2011, **30**:118–124.
37. Lopman BA, Curns AT, Yen C, Parashar UD: **Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States.** *J Infect Dis* 2011, **204**:980–986.
38. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heise JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM, Rotavirus Efficacy and Safety Trial (REST) Study Team, Rotavirus Efficacy and Safety Trial (REST) Study Team: **Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.** *N Engl J Med* 2006, **354**:23–33.
39. Cortese MM, Parashar UD, Centers for Disease Control and Prevention (CDC): **Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP).** *MMWR Recomm Rep* 2009, **58**:1–25.
40. Vesikari T, Itzler R, Karyonen A, Korhonen T, Van Damme P, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, Goveia MG: **RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.** *Vaccine* 2009, **28**:345–351.
41. Anderson EJ: **Rotavirus vaccines: viral shedding and risk of transmission.** *Lancet Infect Dis* 2008, **8**:642–649.
42. Goossens L, Standaert B, Hartwig N, Hovels AM, Al MJ: **Conclusion on cost-effectiveness of rotavirus vaccination highly dependent on assumptions.** *Vaccine* 2009, **27**:2531–2532.
43. Syriopoulou V, Kafetzis D, Theodoridou M, Syrogiannopoulos GA, Mantagos S, Trimis G, Mavrikou M, Konstantopoulos A: **Evaluation of potential medical and economic benefits of universal rotavirus vaccination in Greece.** *Acta Paediatr* 2011, **100**:732–739.
44. Marsella M, Raimondi L, Bergamini M, Sprocati M, Bigi E, De Sanctis V, Borgna-Pignatti C, Gabutti G: **Epidemiology of rotavirus-associated hospital admissions in the province of Ferrara, Italy.** *Eur J Pediatr* 2009, **168**:1423–1427.
45. Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL: **Protection from rotavirus reinfection: 2-year prospective study.** *J Infect Dis* 1991, **164**:277–283.
46. Ward RL, Bernstein DI: **Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group.** *J Infect Dis* 1994, **169**:900–904.
47. Velázquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, Glass RI, Estes MK, Pickering LK, Ruiz-Palacios GM: **Rotavirus infections in infants as protection against subsequent infections.** *N Engl J Med* 1996, **335**:1022–1028.
48. Pitzer VE, Atkins KE, Frieseleben de Blasio B, Van Effelterre T, Atchison CJ, Harris JP, Shim E, Galvani AP, Edmunds WJ, Viboud C, Patel MM, Grenfell BT, Parashar DU, Lopman BA: **Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models.** *PLoS One* 2012, **7**:e42320.

doi:10.1186/1471-2334-13-112

Cite this article as: Zlamy et al.: The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. *BMC Infectious Diseases* 2013 **13**:112.